Alvine Pharmaceuticals is developing innovative therapeutic and diagnostic products for the treatment of celiac disease, a gluten-induced autoimmune disease for which no drug therapy is presently available. Based on technology created at Stanford and the Celiac Sprue Research Foundation, Alvine Pharmaceuticals plans to become the leader in developing new drugs to treat celiac disease and other immune related diseases of the gastrointestinal tract.

Flagship General Partner Doug Cole is an Observer on the Board of Directors.

www.alvinepharma.com